Significance of L-carnitine in internal medicine


Cite item

Full Text

Abstract

The review presents the results of a number of experimental and clinical studies proving the prospects of using L-carnitine in the clinic of internal diseases. Due to the antioxidant and antihypoxant properties, the additional use of L-carnitine in addition to the main etiopathogenetic therapy is prescribed by cardiologists, nephrologists, neurologists, gerontologists. Experimental studies we conducted earlier showed no effect of L-carnitine on the activity of the P450 CYP 3A4 system, which reduces the likelihood of drug-drug interaction at the level of metabolism of drugs metabolized by P450 3A4. When using L-carnitine as part of complex pharmacotherapy, the drug has an increased safety profile in comorbid patients taking L-carnitine.

About the authors

Zh M Sizova

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: sizova-klinfarma@mail.ru
д.м.н., проф., директор Методического центра аккредитации специалистов; ORCID: 0000-0002-1242-7074 Москва, Россия

E V Shikh

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: chih@mail.ru
д.м.н., проф., зав. каф. клинической фармакологии и пропедевтики внутренних болезней; ORCID: 0000-0001-6589-7654 Москва, Россия

A A Makhova

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: annabramova@gmail.com
к.м.н., доцент каф. клинической фармакологии и пропедевтики внутренних болезней; ORCID: 0000-0001-9817-9886 Москва, Россия

References

  1. Кyкec В.Г., Сычев Д.А. Пepcoнaлизиpoвaннaя мeдицинa: нoвыe вoзмoжнocти для пoвышeния бeзoпacнocти фapмaкoтepaпии. Peмeдиyм. 2010;(10):38-40.
  2. Мaxoвa A.A. Влияниe нaгpyзoчныx дoз витaминoв гpyппы B нa фapмaкoкинeтикy и фapмaкoдинaмикy НПВC: диc. … кaнд. мeд. нayк. М., 2010; 107 c.
  3. Rebouche C.J. Carnitine. In: Shils M.E, Shike M, Ross A.C, Caballero B, Cousins R.J, eds. Modern Nutrition in Health and Disease. 10th ed. Philadelphia: Lippincott, Williams & Wilkins; 2006:537-544.
  4. Rebouche C.J. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann NY Acad Sci. 2004;1033:30-41.
  5. De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabeic neuropathy. A long - term, randomised, double - blind, placebo - controlled study. Drugs RD. 2002;3(4):223-31.
  6. Gross C.J, Henderson L.M, Savaiano D.A. Uptake of L-carnitine, D-carnitine and acetyl-L-carnitine by isolated guinea - pig enterocytes. Biochim Biophys Acta. 1986;886(3):425-33.
  7. Foster D.W. The role of the carnitine system in human metabolism. Ann NY Acad Sci. 2004;1033:1-16.
  8. Асташкин Е.И., Глезер М.Г. Роль L-карнитина в энергетичесокм обмене кардиомиоцитов и лечении заболеваний сердечно - сосудистой системы. Кардиология и сердечно - сосудистая хирургия. 2012;6(2):58-65.
  9. Lombard K.A, Olson A.L, Nelson S.E, Rebouche C.J. Carnitine status of lactoovovegetarians and strict vegetarian adults and children. Am J Clin Nutr. 1989;50(2):301-6.
  10. Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion - dependent carnitine transporter. Nat Genet. 1999;21(1):91-4.
  11. Stanley C.A. Carnitine deficiency disorders in children. Ann NY Acad Sci. 2004;1033:42-51.
  12. Seim H, Eichler K, Kleber H. L(-)-Carnitine and its precursor, gamma - butyrobetaine. In: Kramer K, Hoppe P, Packer L, eds. Nutraceuticals in Health and Disease Prevention. New York: Marcel Dekker, Inc; 2001:217-256.
  13. Pons R, De Vivo D.C. Primary and secondary carnitine deficiency syndromes. J Child Neurol. 1995;10(Suppl 2):8-24.
  14. Calvani M, Benatti P, Mancinelli A, et al. Carnitine replacement in end - stage renal disease and hemodialysis. Ann NY Acad Sci. 2004;1033:52-66.
  15. Food and Nutrition Board, Institute of Medicine. Vitamin C. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington D.C.: National Academy Press; 2000:95-185.
  16. Costell M, O'Connor J.E, Grisolia S. Age - dependent decrease of carnitine content in muscle of mice and humans. Biochem Biophys Res Commun. 1989;161(3):1135-43.
  17. Hagen T.M, Ingersoll R.T, Wehr C.M, et al. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci USA. 1998;95(16):9562-6.
  18. Pesce V, Fracasso F, Cassano P, Lezza A.M, Cantatore P, Gadaleta M.N. Acetyl-L-carnitine supplementation to old rats partially reverts the age - related mitochondrial decay of soleus muscle by activating peroxisome proliferator - activated receptor gamma coactivator-1alpha - dependent mitochondrial biogenesis. Rejuvenation Res. 2010;13(2-3):148-51.
  19. Gomez L.A, Heath S.H, Hagen T.M. Acetyl-L-carnitine supplementation reverses the age - related decline in carnitine palmitoyltransferase 1 (CPT1) activity in interfibrillar mitochondria without changing the l - carnitine content in the rat heart. Mech Ageing Dev. 2012;133(2-3):99-106.
  20. Hagen T.M, Liu J, Lykkesfeldt J, et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci USA. 2002;99(4):1870-5.
  21. Liu J, Head E, Gharib A.M, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha - lipoic acid. Proc Natl Acad Sci USA. 2002;99(4):2356-61.
  22. Davini P, Bigalli A, Lamanna F, Boem A. Controlled study on L-carnitine therapeutic efficacy in post - infarction. Drugs Exp Clin Res. 1992;18(8):355-65.
  23. Xue Y.Z, Wang L.X, Liu H.Z, Qi X.W, Wang X.H, Ren H.Z. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction. Cardiovasc Drugs Ther. 2007;21(6):445-8.
  24. Iyer R, Gupta A, Khan A, Hiremath S, Lokhandwala Y. Does left ventricular function improve with L-carnitine after acute myocardial infarction? J Postgrad Med. 1999;45(2): 38-41.
  25. Colonna P, Iliceto S. Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. Am Heart J. 2000;139(2 Pt 3):124-30.
  26. Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol. 1995;26(2):380-7.
  27. Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S. Metabolic treatment with L-Carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology. 2006;106(4):215-23.
  28. Семиголовский Н.Ю., Верцинский Е.К., Азанов Б.А., Иванова Е.В. Положительные инотропные свойства левокарнитина при синдроме малого выброса у больных острым инфарктом миокарда. Кардиология и cердечно - сосудистая хирургия. 2013;(3):43-6.
  29. Глезер М.Г., Киселева А.Е., Асташкин Е.И. Влияние L-карнитина на дисперсию интервала QT у пациентов с острым коронарным синдромом. Кардиология. 2015;55(3):4-9.
  30. Глезер М.Г., Киселева А.Е., Асташкин Е.И Влияние L-карнитина на ЧCC и QTс у пациентов с острым коронарным синдромом. Сердце. 2015;14(2/82):78-84.
  31. Глезер М.Г., Киселева А.Е., Прокофьева Е.Б., Асташкин Е.И. Влияние L-карнитина на эхокардиографические показатели у пациентов с острым коронарным синдромом. Журнал Сердечная Недостаточность. 2015;16(4):234-40.
  32. Асташкин Е.И., Глезер М.Г. Влияние L-карнитина на оксидативный стресс при сердечно - сосудистых заболеваниях. Медицинский Совет. 2016;10:94-100.
  33. Асташкин Е.И., Глезер М.Г., Орехова Н.С., Грачев С.В., Киселева А.Е. Влияние L-карнитина на образование радикалов кислорода фагоцитами крови пациентов с постинфарктным кардиосклерозом. Кардиоваскулярная терапия и профилактика. 2016;15(5):28-32.
  34. Rizos I. Threeyear survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J. 2000;139(2 Pt 3):120-3.
  35. Xiaolong Song, Huiyan Qu, Zongguo Yang, Jingfeng Rong, Wan Cai and Hua Zhou. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. BioMed Research International. 2017;(2017). Article ID 6274854, 11 p. doi: 10.1155/2017/6274854
  36. Cacciatore L, Cerio R, Ciarimboli M, et al. The therapeutic effect of L-carnitine in patients with exercise - induced stable angina: a controlled study. Drugs Exp Clin Res. 1991;17(4):225-35.
  37. Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double - blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol. 1985;23(10):569-72.
  38. Iyer R.N, Khan A.A, Gupta A, Vajifdar B.U, Lokhandwala Y.Y. L-carnitine moderately improves the exercise tolerance in chronic stable angina. J Assoc Physicians India. 2000;48(11):1050-2.
  39. Di Nicolantonio J.J, Lavie C.J, Fares H, et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta - analysis. Mayo Clin Proc. 2013;88(6):544-51.
  40. Guarnieri G, Situlin R, Biolo G. Carnitine metabolism in uremia. Am J Kidney Dis. 2001;38(4 Suppl 1):63-7.
  41. Hurot J.M, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol. 2002;13(3):708-14.
  42. Kazmi W.H, Obrador G.T, Sternberg M, et al. Carnitine therapy is associated with decreased hospital utilization among hemodialysis patients. Am J Nephrol. 2005;25(2):106-15.
  43. Weinhandl E.D, Rao M, Gilbertson D.T, Collins A.J, Pereira B.J. Protective effect of intravenous levocarnitine on subsequent - month hospitalization among prevalent hemodialysis patients, 1998 to 2003. Am J Kidney Dis. 2007;50(5):803-12.
  44. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Diseases. 2000;35(6 Suppl 2):1-140.
  45. Eknoyan G, Latos D.L, Lindberg J. Practice recommendations for the use of L-carnitine in dialysis - related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis. 2003;41(4):868-76.
  46. Schreiber B. Safety of oral carnitine in dialysis patients. Semin Dial. 2002;15(1):7
  47. Wei X-J, Han M, Wei G-C, Duan C-H. Prognostic value of cerebrospinal fluid free fatty acid levels in patients with acute ischemic stroke. Frontiers in Human Neuroscience. 2015;9:402. doi: 10.3389/fnhum.2015.00402.
  48. Головкин В., Зуев А., Привалова М. и др. Когнитивные нарушения и кардиореспираторная дисфункция при дисциркуляторной энцефалопатии с кардиоцеребральным синдромом. Врач. 2018;29(4):51-3. doi: 10.29296/25877305-2018-04-09
  49. Гусев Е.И., Кузин В.М., Колесникова Т.Н. и др. Карнитин - ведущий фактор регенерации нервной ткани. Медицинский информационный вестник. 1999 (февраль):11-23.
  50. Бодыхов М.К., Стаховская Л.В., Салимов К.А., Сун Чер И. Оценка безопасности и эффективности препарата «Элькар» (левокарнитин) у пациентов в остром периоде ишемического инсульта в каротидной системе. РМЖ - Неврология. 2011;11:3-6.
  51. Чичановская Л.В., Бахарева О.Н., Сорокина К.Б. Исследование безопасности и эффективности L-карнитина у больных в раннем восстановительном периоде ишемического инсульта. Журнал неврологии и психиатрии им С.С. Корсакова. 2017;12(Вып. 2):65-9.
  52. Makhova A.A, Shich E.V, Kukes V.G, Sizova O.S, Ramenskaya G.V, Shumyantseva V.V, Bulko T.V, Archakov A.I, Usanov S.A. Electroanalysis of cytochrome P450 3A4 catalytic properties with nanostructured electrodes: the influence of vitamin B group on diclofenac metabolism. BioNanoScience. 2011;1(1-2):46-52.
  53. Махова А.А., Шумянцева В.В., Ших Е.В., Булко Т.В., Супрун Е.В., Кузиков А.В., Кукес В.Г., Арчаков А.И. Регуляция активности ферментов метаболизма лекарственных препаратов - цитохромов Р450 3А4 и 2С9 - биологически активными соединениями. Молекулярная медицина. 2013;(5):49-53.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies